Insufficient response to mRNA SARS-CoV-2 vaccine and high incidence of severe COVID-19 in kidney transplant recipients during pandemic

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00669806%3A_____%2F22%3A10437401" target="_blank" >RIV/00669806:_____/22:10437401 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216208:11140/22:10437401

Výsledek na webu

<a href="https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=FFR.0N5ZjW" target="_blank" >https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=FFR.0N5ZjW</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1111/ajt.16902" target="_blank" >10.1111/ajt.16902</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Insufficient response to mRNA SARS-CoV-2 vaccine and high incidence of severe COVID-19 in kidney transplant recipients during pandemic

Popis výsledku v původním jazyce

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) mRNA vaccination may fail to sufficiently protect transplant recipients against coronavirus disease 2019 (COVID-19). We retrospectively evaluated COVID-19 in kidney transplant recipients (n=226) after BNT162b2 mRNA vaccine administration. The control group consisted of unvaccinated patients (n=194) during the previous pandemic wave. We measured anti-spike protein immunoglobulin G (IgG) levels and cellular responses, using enzyme-linked immunosorbent spot assay, in a prospective cohort after vaccination (n=31) and recovery from COVID-19 (n=19). COVID-19 was diagnosed in 37 (16%) vaccinated and 43 (22%) unvaccinated patients. COVID-19 severity was similar in both groups, with patients exhibiting a comparable need for hospitalization (41% vs. 40%, P=1.000) and mortality (14% vs. 9%, P=0.726). Short post-transplantation periods were associated with COVID-19 after vaccination (P&lt;0.001). Only 5 (16%) patients achieved positive SARS-CoV-2 IgG after vaccination, and 17 (89%, P&lt;0.001) recovered from COVID-19 (median IgG levels, 0.6 vs. 52.5 AU/mL, P&lt;0.001). A cellular response following vaccination was present in the majority (n=22, 71%), with an increase in interleukin 2 secreting T cells (P&lt;0.001). Despite detectable T-cell immunity after mRNA vaccination, kidney transplant recipients remained at a high risk of severe COVID-19. Humoral responses induced by vaccination were significantly lower than that after COVID-19.

Název v anglickém jazyce

Insufficient response to mRNA SARS-CoV-2 vaccine and high incidence of severe COVID-19 in kidney transplant recipients during pandemic

Popis výsledku anglicky

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) mRNA vaccination may fail to sufficiently protect transplant recipients against coronavirus disease 2019 (COVID-19). We retrospectively evaluated COVID-19 in kidney transplant recipients (n=226) after BNT162b2 mRNA vaccine administration. The control group consisted of unvaccinated patients (n=194) during the previous pandemic wave. We measured anti-spike protein immunoglobulin G (IgG) levels and cellular responses, using enzyme-linked immunosorbent spot assay, in a prospective cohort after vaccination (n=31) and recovery from COVID-19 (n=19). COVID-19 was diagnosed in 37 (16%) vaccinated and 43 (22%) unvaccinated patients. COVID-19 severity was similar in both groups, with patients exhibiting a comparable need for hospitalization (41% vs. 40%, P=1.000) and mortality (14% vs. 9%, P=0.726). Short post-transplantation periods were associated with COVID-19 after vaccination (P&lt;0.001). Only 5 (16%) patients achieved positive SARS-CoV-2 IgG after vaccination, and 17 (89%, P&lt;0.001) recovered from COVID-19 (median IgG levels, 0.6 vs. 52.5 AU/mL, P&lt;0.001). A cellular response following vaccination was present in the majority (n=22, 71%), with an increase in interleukin 2 secreting T cells (P&lt;0.001). Despite detectable T-cell immunity after mRNA vaccination, kidney transplant recipients remained at a high risk of severe COVID-19. Humoral responses induced by vaccination were significantly lower than that after COVID-19.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30213 - Transplantation

Projekt

<a href="/cs/project/EF16_019%2F0000787" target="_blank" >EF16_019/0000787: Centrum výzkumu infekčních onemocnění</a><br>

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2022

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

American Journal of Transplantation

ISSN

1600-6135

e-ISSN

1600-6143

Svazek periodika

22

Číslo periodika v rámci svazku

3

Stát vydavatele periodika

US - Spojené státy americké

Počet stran výsledku

12

Strana od-do

801-812

Kód UT WoS článku

000728586100001

EID výsledku v databázi Scopus

2-s2.0-85120869169